The only available automated test to determine the procoagulant activity of phospholipids.
This innovating test is an indirect marker of Tissue Factor exposure In Vivo.
Your connexion to coagulation expertise.
STA®-Rivaroxaban Calibrator & STA®-Rivaroxaban Control*
Rivaroxaban is a new oral anticoagulant developed by Bayer HealthCare and sold under the trade name Xarelto®. It is a direct factor Xa inhib...
How can haemophilia A and type 2N von Willebrand disease be distinguished? To answer this question, Stago has developed a new diagnostic too...
Stago is the market leader in the supply of Haemostasis products within the ANZ market.
Our ANZ head office and training facilities are located in Doncaster, and we have a presence in most states of Australia and both islands in New Zealand.
Our team is highly specialised, and able to support you in the field of Haemostasis.
Stago’s first mission is to provide health professionals with reliable, powerful and innovative haemostasis diagnostic tools in looking for a way to improve prevention, understanding, diagnostic, treatment and follow-up of coagulation-related pathologies.
October 28 -31, 2012
October 29, 2011
October 30 - November 2, 2011
Did you know?
Heparin was discovered independently in 1911 by Doyon and in 1916 by McLean, for different reasons. The effect of heparin on blood clotting, however, had been observed one-third of a century earlier.
Recent Jobs
We don't have any job openings at the moment. Please check back later. If you would still like to apply, you are welcome to send us an application enquiry.
Apply
